Stock of the Day

Zoetis (ZTS)

$78.92

+$0.50 (+0.6%)

Market Cap: $32.63B

About Zoetis

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally.

The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

Zoetis Bull Case

Here are some ways that investors could benefit from investing in Zoetis Inc.:

• Zoetis Inc. currently trades at $75.34, which is significantly below the consensus price target of $101.08 set by Wall Street analysts, suggesting substantial upside potential for investors who believe the market is currently undervaluing the company's long-term prospects.
• The company offers a dividend yield of 2.85%, with a recent declaration of $0.53 per share for the fourth quarter of 2026, providing a steady income stream that is supported by a sustainable payout ratio of approximately 31% to 35% of earnings.
• Zoetis Inc. demonstrated strong operational performance in the most recent quarter, reporting earnings per share of $1.87, which exceeded the analyst consensus estimate of $1.85, indicating that the company is effectively managing costs and generating profit despite revenue headwinds.
• Recent peer-reviewed research published in October 2026 showed that Zoetis Inc.'s Simparica Trio product protected three times more dogs from infection with resistant heartworm isolates than a rival product, reinforcing the company's competitive advantage in the animal health market.
• Institutional investors are increasing their confidence in the stock, as evidenced by Moody National Bank Trust Division boosting its stake by 108.5% and Rockland Trust Co. raising its holdings by 19.8% in the third quarter, signaling that professional money managers are accumulating shares at current price levels.

Zoetis Bear Case

Investors should be bearish about investing in Zoetis Inc. for these reasons:

• The stock has experienced a significant decline, hitting a 52-week low of $68.77 in September 2026, which is nearly 50% below its 52-week high of $148.30, indicating a severe loss of investor confidence and substantial downside risk over the past year.
• Zoetis Inc. issued full-year 2026 guidance for earnings per share of $6.15 to $6.25, which is well below the analyst consensus estimate of $6.87, suggesting that the company expects continued financial pressure and lower profitability than the broader market anticipates.
• Revenue growth has stalled, with the most recent quarter showing a year-over-year revenue decline of 0.2% and actual revenue of $2.47 billion falling short of the $2.50 billion analyst estimate, highlighting challenges in driving top-line growth in the current market environment.
• Wall Street analysts have consistently lowered their price targets over the past few months, with recent cuts from firms like TD Cowen, Stifel Nicolaus, and Piper Sandler reflecting a bearish outlook on the company's ability to recover its previous valuation levels.
• The company carries a high debt-to-equity ratio of 2.87, which indicates a significant level of leverage that could constrain financial flexibility and increase risk during periods of economic uncertainty or lower cash flow generation.

Recent News

• Zoetis’ Valuation Has Fallen Sharply, but Has the Market Overreacted? (insidermonkey.com)
• 3 Reasons ZTS is Risky and 1 Stock to Buy Instead (finance.yahoo.com)
• Zoetis (ZTS) Hit by Guidance Cuts, Met with Market Shrug (finance.yahoo.com)
• Zoetis Inc. stock underperforms Wednesday when compared to competitors despite daily gains (marketwatch.com)
• Zoetis (ZTS) Board Update And Dividend Keep Undervalued Narrative In Focus (finance.yahoo.com)
• Branded Pharmaceuticals Stocks Q2 In Review: Zoetis (NYSE:ZTS) Vs Peers (finance.yahoo.com)
• Zoetis Appoints Iris Knobloch to Board of Directors (tipranks.com)
• Zoetis Appoints Iris Knobloch to its Board of Directors (businesswire.com)
• Zoetis (ZTS) Stock May Trade At A Discount As Q2 Pressure Persists (finance.yahoo.com)